Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...
Genomics (NASDAQ:TXG – Free Report) had its price objective decreased by UBS Group from $20.00 to $14.00 in a research report ...
Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...
Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...
CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales reorganization and grow base of industry users.
We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...
10x Genomics disclaims any intention or obligation ... I'll start with the product innovations we introduced in 2024. First on our Chromium platform. Last year was the biggest year of Chromium ...
10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium instruments and $13.43 million from Spatial instruments.